BHCM
AMLX icon

Boulder Hill Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Boulder Hill Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,400
Closed -$276K – 90
2023
Q1 		$276K Buy
+9,400
New +$327K 0.22% 92

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Boulder Hill Capital Management's AMLX Position: Q2 2023 in Review

Boulder Hill Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2023, closing a stake of 9,400 shares — an estimated $276K sold.

Boulder Hill Capital Management first reported a position in AMLX in Q1 2023 and held it in 1 quarter. The position peaked at $276K in Q1 2023. 154 funds tracked by Wall St. Rank hold AMLX as of Q2 2023.

  • Boulder Hill Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 9,400 Amylyx Pharmaceuticals shares in Q2 2023, an estimated $276K.
  • Boulder Hill Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Boulder Hill Capital Management's Amylyx Pharmaceuticals position peaked at $276K in Q1 2023.
  • 154 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2023.

Based on Boulder Hill Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.